Bristol-Myers Squibb Announces Charitable Donation of $1 Million to Support Immuno-Oncology Education for Patients and

  Bristol-Myers Squibb Announces Charitable Donation of $1 Million to Support
  Immuno-Oncology Education for Patients and Caregivers

Business Wire

PRINCETON, N.J. -- March 3, 2014

Bristol-Myers Squibb Company today announced donations totaling $1 million in
2013 to four nonprofit organizations that support patients with cancer. The
donations will fund the development and availability of educational materials
for patients and caregivers about the emerging field of cancer research and
treatment called immuno-oncology. Bonnie Addario Lung Cancer Foundation,
Cancer Support Community, LUNGevity, and Society for Immunotherapy of Cancer
each received a $250,000 charitable contribution to advance their independent
educational initiatives.

“Bristol-Myers Squibb is committed to leading advances in immuno-oncology,
from early discovery and clinical development to providing education and
access to care for patients,” said Joseph Leveque, MD, vice president,
Oncology, U.S. Medical, Bristol-Myers Squibb. “We are proud to support these
organizations in their efforts to help educate patients and caregivers about
this rapidly evolving area of cancer research and treatment.”

Surgery, radiation, cytotoxic or targeted therapies have represented the
mainstay of cancer treatment over the last several decades, but long-term
survival and a positive quality of life have remained elusive for many
patients with advanced disease. To address this unmet medical need,
Bristol-Myers Squibb is leading advances in immuno-oncology.

Immuno-oncology is based on the premise that the immune system is the body’s
most powerful and effective tool for recognizing and fighting disease. Unlike
traditional therapies that target the tumor, immuno-oncology agents are
designed to harness the natural capabilities of the patient’s immune system to
fight cancer by targeting the very same pathways that tumor cells use to evade
recognition and distribution. The goal of immuno-oncology is to change
survival expectations and the way that patients live with cancer.

Visit www.lungcancerfoundation.org, www.cancersupportcommunity.org,
www.lungevity.org, and www.sitcancer.org to learn more about these
organizations.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to
discovering, developing and delivering innovative medicines that help patients
prevail over serious diseases. For more information about Bristol-Myers
Squibb, visit www.bms.com, or follow us on Twitter at
http://twitter.com/bmsnews.

Contact:

Bristol-Myers Squibb
Media:
Chrissy Trank, 609-252-3418
christina.trank@bms.com
or
Investors:
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com
or
Ryan Asay, 609-252-5020
ryan.asay@bms.com
 
Press spacebar to pause and continue. Press esc to stop.